AIDS Vaccine Nearing Reality

[Guest guest]

Even though HIV has never been proven to 'cause' AIDS

http://www.nccn.net/~wwithin/AIDS.htm

lots of money to be made from so-called vaccine

PUSHING HPV vaccine is a test for the acceptability of this one

Sheri

" The vaccine uses a decoy virus with some of the genetic material of the

aids virus but not enough for anyone to ever get the disease itself from

the shot, according to Dr. Harriet , Ph. D., of the Emory Vaccine

Center. " It exposes your immune system to a pathogen like a virus or

bacteria so before you've seen it you set up memory cells,” Dr.

said, “and then these memory cells mobilize should you get the actual

infection. " The test trials have been so successful that the vaccine is now

more than a year ahead of schedule. " Actually another two trials are

starting later this year using different combinations of our vaccine and

different administration programs,” said GeoVax CEO Hildebrand. “And

following that presuming everything goes well we'll be starting a phase two

program at the end of the year. " The vaccine works using a one-two

pharmaceutical punch to prime the body then kill the virus. “It raises both

antibodies that can block the virus and it raises white blood cells called

t cells that can kill the virus infected cells,” said Dr. . “So it

really has two methods of controlling an HIV/AIDS infection once it enters

the body. " - Whitney, WXIA-TV, Atlanta

" Two of the most advanced [HIV vaccine] trials underway in 2007 are from

Sanofi-Pasteur and Merck & Co., Inc. Data from Merck's ongoing Phase IIb

test-of-concept trial with its adeno-5 vector vaccine candidate is expected

in 2008-2009 and will provide preliminary information on the efficacy of

this type of [HIV] vaccine candidate. These results will have significant

implications for the field's future research and development efforts. The

company will also soon be starting an additional Phase IIb [HIV vaccine]

trial with the same candidate in South Africa. " - News-Medical.net

AIDS Vaccine Nearing Reality at Emory

WXIA-TV Atlanta

March 9, 2007

By Whitney

http://www.firstcoastnews.com/news/news-article.aspx?storyid=77571

ATLANTA, GA -- The world could have a new vaccine designed to kill the

AIDS virus in as little as three to four years according to an

Atlanta-based group working on the vaccine.

It is a scientific advance that could save tens of millions of lives, and

it is being developed on the campus of Emory University.

The work has been going on quietly for the last 15 years. But now it

appears headed for the bell lap in the race to prevent the disease.

And the Atlanta-based group may be way ahead of the rest of the world.

The GeoVax lab at Emory is smaller than many garages. And yet the small

modular building may be where the battle to end the reign of one the

world's biggest killers could be won with a vaccine to prevent AIDS.

" We're getting results back that indicate we're getting very strong immune

responses in these individuals these people who received our vaccine, " said

Don Hildebrand, the president and CEO of GeoVax Inc., the company

spearheading the research in collaboration with Emory, the Centers for

Disease Control, and the National Institutes of Health.

The vaccine uses a decoy virus with some of the genetic material of the

aids virus but not enough for anyone to ever get the disease itself from

the shot, according to Dr. Harriet , Ph. D., of the Emory Vaccine

Center.

" It exposes your immune system to a pathogen like a virus or bacteria so

before you've seen it you set up memory cells,” Dr. said, “and

then these memory cells mobilize should you get the actual infection. "

The test trials have been so successful that the vaccine is now more than a

year ahead of schedule.

" Actually another two trials are starting later this year using different

combinations of our vaccine and different administration programs,” said

GeoVax CEO Hildebrand. “And following that presuming everything goes well

we'll be starting a phase two program at the end of the year. "

The vaccine works using a one-two pharmaceutical punch to prime the body

then kill the virus.

“It raises both antibodies that can block the virus and it raises white

blood cells called t cells that can kill the virus infected cells,” said

Dr. . “So it really has two methods of controlling an HIV/AIDS

infection once it enters the body. "

The vaccine’s success with the simian AIDS virus has been nothing short of

remarkable. Not only did the vaccine prevent the infection, it kept it

under control for the monkeys that already had it, putting it in a kind of

remission.

Researchers believe the same benefits await human subjects.

----------------------------------------------------------------------------

----------------------------------------------

13 new AIDS vaccine clinical trials initiated in 2006

News-Medical.net

Published Tuesday, Feb. 6,

2007<http://rs6.net/tn.jsp?t=6ztag5bab.0.vjlcg5bab.oblmlwbab.8914 & ts=S0235 & p

=http%3A%2F%2Fwww.news-medical.net%2F%3Fid%3D21730>Click here for the URL:

<http://rs6.net/tn.jsp?t=6ztag5bab.0.xjlcg5bab.oblmlwbab.8914 & ts=S0235 & p=htt

p%3A%2F%2Fwww.iavi.org%2F>The International AIDS Vaccine Initiative's

(IAVI) January 2007 Annual Issue of VAX, an editorially independent

bulletin on AIDS vaccine research published by IAVI, reports that 13 new

preventive AIDS vaccine trials were initiated in eight countries around the

world in 2006. There are now more than 30 trials ongoing in 24 countries,

across every continent.

This annual publication provides the only comprehensive listing of all

AIDS vaccine clinical trial activity worldwide.

Last year saw the start of the first AIDS vaccine trials in the Russian

Federation and Zambia, and three countries in sub-Saharan Africa -Kenya,

Uganda, and Tanzania-also initiated new trials. The United States, United

Kingdom, Sweden and Peru began new trials in 2006 as well. Many of these

trials were sponsored by new research groups, including the Karolinska

Institute in Sweden, St. 's University of London and the Moscow

Institute of Immunology.

All of the new trials that began last year were either Phase I or Phase

I/II trials designed to evaluate the safety and immunogenicity of the

candidate vaccines. " Although these new trials are early-stage, they will

provide critical information over the coming years that will help drive the

field's R & D agenda. We hope to begin to see even more novel vectors, as

well as approaches that target neutralizing antibodies in the next few

years, " said CEO and President of IAVI, Dr. Seth Berkley.

IAVI and its collaborators are currently conducting four ongoing trials in

India, Kenya, Rwanda, Uganda, South Africa and the United States. In 2006,

IAVI launched a Phase II trial in Uganda and Zambia, part of a multi-site

study that also included three sites in South Africa. The South Africa,

Uganda and Zambia trial sites are now fully enrolled with data expected

later this year.

Two of the most advanced trials underway in 2007 are from Sanofi-Pasteur

and Merck & Co., Inc. Data from Merck's ongoing Phase IIb test-of-concept

trial with its adeno-5 vector vaccine candidate is expected in 2008-2009

and will provide preliminary information on the efficacy of this type of

vaccine candidate. These results will have significant implications for the

field's future research and development efforts. The company will also soon

be starting an additional Phase IIb trial with the same candidate in South

Africa.

The Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates that 4.3

million people were newly infected with HIV last year-bringing the total

number of HIV-infected individuals to 40 million people worldwide.

Explosive HIV epidemics also continue in Eastern Europe and Central Asia.

Throughout the world, a preventive AIDS vaccine remains one of the greatest

hopes for stemming the pandemic.

--------------------------------------------------------

Sheri Nakken, R.N., MA, Hahnemannian Homeopath

Vaccination Information & Choice Network, Nevada City CA & Wales UK

$$ Donations to help in the work - accepted by Paypal account

earthmysteriestours@... voicemail US 530-740-0561

(go to http://www.paypal.com) or by mail

Vaccines - http://www.nccn.net/~wwithin/vaccine.htm

Vaccine Dangers On-Line course - http://www.nccn.net/~wwithin/vaccineclass.htm

Reality of the Diseases & Treatment -

http://www.nccn.net/~wwithin/vaccineclass.htm

Homeopathy On-Line course - http://www.nccn.net/~wwithin/homeo.htm